New therapeutic "cocktails" could offer long-lasting relief for treatment-resistant asthma and other inflammatory diseases of ...

The cocktails inhibit key molecules (called ICOSL, OX40L, and CD30L) that they found allow specialized tissue-resident memory T cells to stay active and maintained in high numbers in tissues.

The cocktails inhibit key molecules (called ICOSL, OX40L, and CD30L) that they found allow specialized tissue-resident memory T cells to stay active and maintained in high numbers in tissues.

Apogee Therapeutics, Inc. announced positive interim Phase 1 results for its novel OX40L antibody, APG990, which demonstrated a half-life of approximately 60 days and potential for infrequent dosing.

The cocktails inhibit key molecules (called ICOSL, OX40L, and CD30L) that they found allow specialized tissue-resident memory T cells to stay active and maintained in high numbers in tissues.

The problematic molecules—ICOSL, OX40L, and CD30L—keep memory T cells in the lungs on high alert. While typically these T cells are beneficial, preserving information about past infections to ...

Poster Presentation Title: A First-in-Human Phase 1a Randomized, Double-Blind Single-Ascending Dose Study of NAV-240, an anti-OX40L/TNF-alpha Bispecific Antibody, in Healthy Volunteers Presenter ...